MedWatch

Bioporto makes management change

Diagnostics group Bioporto has made some changes to its management team, with a familiar face taking over as COO come September.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MSD's Keytruda fejler i mavekræftstudie

Immunterapien Keytruda fra amerikanske Merck/MSD har ikke kunnet overgå kemoterapi i andenlinjebehandling af patienter med kræft i mave eller spiserør. Lægemidlet blev for få måneder siden godkendt i indikationen i tredje linje.

Latest Top picks in English

Related articles